Overview

Zemaira Eosinophilic Esophagitis Pilot Study

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.

Phase:

Phase 2

Details

Lead Sponsor:

Children's Hospital Medical Center, Cincinnati

Collaborators:

CSL Behring
National Institutes of Health (NIH)

Treatments:

Protease Inhibitors